We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/4/2020 14:18 | Hi pennyfalls. Quite so! The next few weeks will tell us what we need to know here. Having effectively written my investment off here, I am watching with some interest, but cannot say I feel we have lost a heavy hitter, come what may. | lovewinshatelosses | |
30/4/2020 12:41 | Hi, I’m a total novice at shares and drug companies but this is my personal view. Having been on STEM Sfx01 and getting great results for me I find it incredibly frustrating that 12 months down from the results there has been no other progress or so it seems. I’m sure I read on here that they were looking at trying to make a tablet form due to the Giant capsule it was in. It wasn’t the smallest capsule but giant it wasn’t it was easy to take and to be fair I take a glucosamine tablet that is much bigger than the capsule. I know things take time but everything seems to be slow so I’m thinking a change in directorship could be a really good thing for the company to try and push things forward on all aspects. Please feel free to give me a polite bashing everyone if I’m talking rubbish! PS I’m well and starting my second new drug next week , it was delayed due to covid19 but we’re starting next week, fingers crossed for a long success on this one. Shielding is a pain but I’m quite liking the slower pace of life and the hubby isn’t divorced yet!! 😀 | blakeysangel | |
30/4/2020 09:34 | Lol, on the contrary, it's more suggestive that he's been forced out and someone more high profile or even potentially connected to a commercial JV will be announced soon, and news on their University collaborations could drop at anytime and every chance this could include SFX-01 being considered for Covid-19 trials. Gl ;-) ps EVG's market cap is a lowly £12m and so plenty of potential UPside as good news rolls in....back to 10p plus in anticipation. ;-) | moneymunch | |
30/4/2020 09:27 | CEO leaving having "decided to pursue other opportunities" is never a good sign. Says it all about the prospects here. Even 3p (where it was before the ramp) is too much. | sicilian_kan | |
30/4/2020 08:26 | Well the market doesn't seem unduly concerned, and so fingers crossed for a high profile replacement waiting in the wings. Gla ;-) | moneymunch | |
30/4/2020 07:44 | I think the answer might be what he hasn’t done. | pennyfalls | |
30/4/2020 07:32 | Lol, yep, not quite the news i was expecting, no notice given and so was he pushed? Should be interesting how quickly his replacement is made, and if someone is already lined up. Gl ;-) | moneymunch | |
30/4/2020 07:22 | Wow. What did he do? | lovewinshatelosses | |
29/4/2020 15:51 | News at anytime and maybe due from their ongoing SFX-01 clinical drug collaborations , with Universities Dundee, Manchester & Rochester, all now heavily involved in Covid-19 research, and highly possible that they could have interest in SFX-01 as a potential compound for the treatment of Covid-19. Gla ;-) | moneymunch | |
29/4/2020 15:26 | Strap yourselves in | peanut100 | |
29/4/2020 14:48 | Interesting indeed. Finncap pushing it better.... | nobbygnome | |
29/4/2020 12:01 | Decent reversal indeed, and 16p plus in a blink on a positive RNS, which could drop at anytime. Gl :-) | moneymunch | |
29/4/2020 11:56 | Decent reversal off today's low. Does this mean that the correction off the recent high is over and that we are headed to a new high-possibly closing the gap around 16? | langland | |
20/4/2020 13:43 | Don’t know about idiot ,definitely clever x | cammy5 | |
20/4/2020 13:35 | Errrrr nope not clever idiot | tialouise | |
20/4/2020 12:00 | 10 to 20 x your cash is that this century | cammy5 | |
19/4/2020 21:26 | Agree. Even higher in the current environment. If one multiplies total invested capital GBP by 10X-20X return Y/number of shares, the upside will surely be very attractive. | mrwizard1 | |
19/4/2020 08:53 | Sorry I meant 5 to 10 times current price, 15p would be blown to pieces | peanut100 | |
18/4/2020 21:49 | 15p would still be extremely under valued. True value only with acquisition by Big Pharma. Long tern investors will want at least 10X. I would be shocked if EVG were not quietly studying utility for COVID-19. | mrwizard1 | |
18/4/2020 18:50 | I agree that if they do announce something Covid related, at least 15p looks nailed on. That would close the gap nicely on the the chart. | nobbygnome | |
18/4/2020 17:05 | I'd be surprised if EVG don't announce something very soon yes or no to confirm this like others have been releasing. If a yes looking at AVCT and SNG you'd think the price will be min 5 to 10 higher. | peanut100 | |
18/4/2020 14:57 | Cheers peanut100, " providing powerful anti-inflammatory and antioxidant protection in the lungs and airways" could be key on why EVG's Sulforadex might be considered for research and development for a potential treatment for respiratory problems associated with Covid-19, and perhaps a high chance that it will given the collaboration agreements they have with several universities that have been developing sulphoraphane based medicines with EVG, who are all now heavily involved in Covid-19 research and treatment development and so perhaps Sulfordex will be given consideration as a potential therapy compound with EVG's collaboration. Gl :-) | moneymunch | |
18/4/2020 11:41 | Great article and find | peanut100 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions